Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02872116 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,031
- Enrollment target
NCT02872116: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT02872116 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 2,031 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (163% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02872116, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,031 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone.
Primary Outcome
Overall survival (OS), defined as the time from randomization to the time of death, in participants treated with Nivolumab plus Chemotherapy vs Chemotherapy with PD-L1 CPS (combined positive score) ≥ 5. CPS is defined as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.
Interventions
- DRUG Capecitabine
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Nivolumab
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,031 participants |
| Start Date | 2016-10-12 |
| Est. Completion | 2024-06-06 |
| Phase | Phase 3 |
What the finished NCT02872116 record still lists
NCT02872116 is an interventional study that assigns participants to a tested intervention. Its 2,031 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (163% higher).
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT02872116 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02872116 about?
NCT02872116 is a clinical study titled "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer". The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone.
What is the current status of trial NCT02872116?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,031 participants. The study started on 2016-10-12. Estimated completion is 2024-06-06.
What interventions are being tested in trial NCT02872116?
The interventions under investigation include: Capecitabine (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02872116?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02872116's enrollment target sits among peer trials
2,031 100th of 2000 higher than 1,901 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05625659 · 2,032 participants · NA
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- NCT04216732 · 2,030 participants
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
- NCT06825897 · 2,039 participants · NA
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
- NCT05138718 · 2,041 participants
FDG an Myocardial Infarction: The PIAF Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI